Skip to main navigation
Compass Therapeutics
  • Home
  • About
  • Platform
  • Pipeline
  • Join Us
  • Investors
  • Contact

In the News

Investor Menu
  • Home
  • News & Events
    • News Releases
    • Events
    • Presentations
    • In the News
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & FIlings
    • SEC Filings
    • Annual Meeting
    • Annual Reports
    • Quarterly Results
6/6/2022
5 Oncology Stocks Wall Street Predicts Will Rally 135% or More
5/4/2022
Compass, AstraZeneca move forward in biliary tract cancer treatments
1/14/2022
Surveying VEGF+DLL4 bids: Compass pointed in favorable direction
9/17/2020
Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study
8/20/2020
Ayala Pharmaceuticals Announces the Appointment of Vered Bisker-Leib, Ph.D. To …
4/6/2020
Compass Therapeutics’ immuno-oncology prospect clears solid tumors in mice
12/11/2019
Nature Reviews Drug Discovery: Immune agonist antibodies face critical test
12/4/2019
BioWorld -Two’s companies: Crowd in bispecifics still growing as methodology so…
10/2/2018
FierceBiotech’s 2018 Fierce 15
7/13/2018
Compass Therapeutics raises $130 million to develop I-O candidate
7/12/2018
Compass Therapeutics eyes possible IPO after $132M investment

IR Contact

Mario Corso, Executive Director and Head of Investor Relations

Mario.corso@compasstherapeutics.com

Media Contact

Anna Gifford, Communications Manager

Anna.Gifford@compasstherapeutics.com

Email Alerts

  • © 2023 Compass Therapeutics, Inc.
  • Terms & Conditions
  • Privacy Policy
  • Home
  • About
  • Platform
  • Pipeline
  • Join Us
  • Investors
  • Contact